07:00 Wed 25 Aug 2021
Feedback PLC - Change of Adviser
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.
Feedback plc
Change of Nominated Adviser and Broker
Dr
-Ends-
Enquiries:
Feedback plc |
+44 (0)1954 718072 |
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or feedbackplc@walbrookpr.com |
|
07980 541 893 or 07748 325 236 or 07884 664 686 |
Notes to Editors
Feedback plc (AIM: FDBK) is a medical imaging technology business with a secure clinical communications platform. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE